Schonfeld Strategic Advisors LLC Invests $187,000 in Verastem, Inc. (NASDAQ:VSTM)

Schonfeld Strategic Advisors LLC acquired a new position in Verastem, Inc. (NASDAQ:VSTM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 36,180 shares of the biopharmaceutical company's stock, valued at approximately $187,000. Schonfeld Strategic Advisors LLC owned about 0.08% of Verastem at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in VSTM. AIGH Capital Management LLC bought a new stake in shares of Verastem during the fourth quarter valued at approximately $13,778,000. Rosalind Advisors Inc. bought a new stake in shares of Verastem during the fourth quarter valued at approximately $4,653,000. Marshall Wace LLP bought a new stake in shares of Verastem during the fourth quarter valued at approximately $4,103,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Verastem during the fourth quarter valued at approximately $328,000. Finally, Geode Capital Management LLC raised its stake in shares of Verastem by 6.5% during the fourth quarter. Geode Capital Management LLC now owns 948,790 shares of the biopharmaceutical company's stock valued at $4,906,000 after acquiring an additional 58,191 shares in the last quarter. Institutional investors own 88.37% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on VSTM shares. Guggenheim lifted their price target on shares of Verastem from $13.00 to $14.00 and gave the company a "buy" rating in a research note on Monday, March 24th. Jefferies Financial Group started coverage on shares of Verastem in a research note on Thursday, April 10th. They set a "buy" rating and a $15.00 price target for the company. HC Wainwright lifted their price target on shares of Verastem from $10.00 to $14.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Royal Bank of Canada decreased their price target on shares of Verastem from $16.00 to $14.00 and set an "outperform" rating for the company in a research note on Friday, March 21st. Finally, Mizuho decreased their price target on shares of Verastem from $9.00 to $8.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. One research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $14.33.

Verastem Stock Down 4.3%

VSTM stock traded down $0.34 during trading on Friday, hitting $7.59. 2,054,556 shares of the company's stock traded hands, compared to its average volume of 1,108,043. The firm has a market capitalization of $417.06 million, a P/E ratio of -2.38 and a beta of 0.85. The business has a fifty day simple moving average of $6.42 and a two-hundred day simple moving average of $5.59. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 2.77. Verastem, Inc. has a 1 year low of $2.10 and a 1 year high of $12.45.

Verastem (NASDAQ:VSTM - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.24). Sell-side analysts anticipate that Verastem, Inc. will post -3.02 EPS for the current year.

Verastem Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.